Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVG321
- Development stage
- Unknown
- Lead developer
- Evergreen Theragnostics
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
EVG321 is a novel radioligand agent developed for both diagnostic and therapeutic applications in small cell lung cancer (SCLC). It consists of a peptide that targets the cholecystokinin 2 receptor (CCK2R), which is highly expressed on SCLC cells. For diagnostics, it is labeled with Gallium-68 (^68Ga) to enable PET/CT imaging, allowing precise visualization and assessment of tumor burden. For therapy, it can be labeled with Lutetium-177 (^177Lu), delivering targeted ionizing radiation to CCK2R-expressing tumors. The mechanism relies on specific binding to CCK2R, facilitating either imaging or localized radiotherapy depending on the isotope used. The drug was originally developed by the Medical University of Innsbruck and is now being advanced by Evergreen Theragnostics[1][3][4][5][6][7].
- Other names
- 68Ga-EVG321Gallium-68 EVG321Gallium68 EVG321Gallium 68 EVG321Lutetium-177 (177Lu) EVG321
02
Targets
CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on EVG321.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVG321.